secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kodiak Sciences Inc. (KOD)
CIK:        0001468748
Form:       8-K
Filed at:   2022-03-01T23:59:59+00:00
Accession:  0000950170-22-002538
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kodiak Sciences Q4 net loss $93.2M; wet AMD pivotal trial misses primary endpoint
--------------------------------------------------------------------------------

- Phase 2b/3 KSI-301 study in wet AMD did not meet non-inferiority vs aflibercept for extended dosing.
- 59% of KSI-301 patients achieved 5-month dosing; safety profile acceptable with no new signals.
- Q4 net loss $93.2M ($1.79/share) vs $46.6M a year ago; full year net loss $267.0M.
- R&D expenses $75.6M in Q4, up from $37.4M, driven by clinical trial and manufacturing costs.
- Cash and equivalents $731.5M; BEACON RVO top-line data expected Q3 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468748/000095017022002538/0000950170-22-002538-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468748/000095017022002538/kod-20220301.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-002538

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer